Lilly Funds Start Up of Biosciences Research Institute - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lilly Funds Start Up of Biosciences Research Institute


The Indiana Biosciences Research Institute (IBRI) reached its first $50-million funding milestone with contributions from corporate and philanthropic funders, including $7.5 million from Eli Lilly, and $25 million appropriated by the Indiana General Assembly earlier this year, IBRI announced in a press release. The funding will fuel continued momentum in the development of the first industry-led biosciences research institute in the US.  

"The IBRI is an R&D model that will help us address some of our most pressing medical needs,” said John C. Lechleiter, PhD, chairman and CEO of Eli Lilly and Company, which is headquartered in Indiana, in a Nov. 2013 company press release. “Despite important advances in recent years, diseases such as diabetes continue to affect our citizens at alarming rates. By pulling together the best minds for collaborative thinking and research, the new institute will help move us closer to solving some of the world's most difficult challenges in health and nutrition."

The non-profit research institute was launched in May 2013 and launched its CEO search in September. The $50 million in start-up funding will be followed by a campaign to raise an additional $310 million in corporate and philanthropic funding to support further Institute development and operating costs. Long-term, Institute operating costs will be funded through the development of the Institute’s own endowment, industry-sponsored research, and federally funded research. As part of the Institute’s development process, industry leaders have defined common scientific interests for research and discovery. The Institute will initially focus on cardiovascular disease, diabetes, obesity, and nutrition.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here